PNC Financial Services Group Inc. Sells 355 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

PNC Financial Services Group Inc. reduced its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 5.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,019 shares of the specialty pharmaceutical company’s stock after selling 355 shares during the quarter. PNC Financial Services Group Inc.’s holdings in ANI Pharmaceuticals were worth $332,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Rubric Capital Management LP grew its stake in ANI Pharmaceuticals by 32.8% during the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock valued at $62,032,000 after acquiring an additional 277,989 shares in the last quarter. Invesco Ltd. lifted its position in shares of ANI Pharmaceuticals by 185.4% in the third quarter. Invesco Ltd. now owns 339,735 shares of the specialty pharmaceutical company’s stock worth $19,725,000 after buying an additional 220,690 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in ANI Pharmaceuticals by 287.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 146,989 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after buying an additional 109,015 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of ANI Pharmaceuticals by 5.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,132,378 shares of the specialty pharmaceutical company’s stock worth $65,746,000 after acquiring an additional 58,204 shares in the last quarter. Finally, Global Alpha Capital Management Ltd. boosted its position in shares of ANI Pharmaceuticals by 10.8% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock valued at $32,115,000 after acquiring an additional 56,900 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Trading Up 0.9 %

NASDAQ ANIP opened at $63.68 on Friday. The stock has a market cap of $1.34 billion, a PE ratio of 39.80 and a beta of 0.81. ANI Pharmaceuticals, Inc. has a 12 month low of $48.20 and a 12 month high of $70.81. The company’s 50-day moving average price is $64.22 and its 200-day moving average price is $61.76. The company has a current ratio of 3.95, a quick ratio of 3.12 and a debt-to-equity ratio of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, May 10th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.16. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. The business had revenue of $137.43 million for the quarter, compared to the consensus estimate of $125.01 million. Equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.37 earnings per share for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $67.25, for a total value of $1,345,000.00. Following the completion of the sale, the senior vice president now directly owns 253,226 shares in the company, valued at $17,029,448.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction on Monday, April 1st. The stock was sold at an average price of $67.25, for a total value of $1,345,000.00. Following the transaction, the senior vice president now directly owns 253,226 shares in the company, valued at approximately $17,029,448.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Ori Gutwerg sold 2,985 shares of the business’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $67.00, for a total value of $199,995.00. Following the completion of the transaction, the senior vice president now directly owns 77,227 shares of the company’s stock, valued at $5,174,209. The disclosure for this sale can be found here. Insiders sold a total of 176,688 shares of company stock valued at $11,408,863 in the last ninety days. Corporate insiders own 12.70% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. HC Wainwright boosted their target price on shares of ANI Pharmaceuticals from $87.00 to $94.00 and gave the stock a “buy” rating in a report on Wednesday. Guggenheim reiterated a “buy” rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. Finally, Capital One Financial initiated coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They set an “overweight” rating and a $80.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $82.75.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.